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Abstract 
 
Background. Plasma fibrinogen is a strong predictor of ischemic arterial disease in women. Sex 
steroid hormones including hormone therapy may play an important role in the development of 
cardiovascular disease. However, whether or not endogenous sex steroid hormones influence the 
plasma fibrinogen concentrations among postmenopausal women remains unclear.   
Objectives. To investigate the association of plasma fibrinogen levels with endogenous sex steroid 
hormones and SHBG among postmenopausal women. 
Methods. We used data from the French prospective Three-City cohort study which included 9,294 
non-institutionalized men and women over 65 years. Total 17-estradiol (E2, pg/ml), total 
Testosterone (T, ng/ml), SHBG (nmol/l) and fibrinogen (g/l) were measured in stored plasmas in a 
subcohort of 602 randomly selected postmenopausal women who used neither hormone 
medication nor anticoagulation therapy. Multivariate linear regression models were used to 
estimate the regression coefficients assessed in fibrinogen unit by 1 SD increase in log-distribution of 
sex steroid hormones and SHBG. .  
Results. E2 but neither T nor SHBG was positively associated with plasma fibrinogen levels (=0.148, 
p<0.001). Adjustment for cardiovascular risk factors including diabetes made no substantial change to 
the results (=0.145 p<0.001). The association of fibrinogen with E2 was stronger among women with 
BMI over 25 kg/m² compared to those with normal weight (=0.156, p<0.001 and =0.092, p=0.02 
respectively, p for interaction=0.04).  
Conclusion. E2 emerges as a positive and independent correlate of plasma fibrinogen among 
postmenopausal women, especially in subjects who are overweight. These findings suggest a 
deleterious effect of endogenous estrogens on cardiovascular risk profile among postmenopausal 
women.  
 
Key words: Fibrinogen, estradiol, testosterone, sex hormone binding globulin, postmenopausal 
women 
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Introduction 
 
Fibrinogen, the fibrin clot precursor, plays a central role in the haemostatic process 1. Elevated plasma 
fibrinogen levels have been shown to be associated with established cardiovascular risk factors 2. In 
particular, plasma fibrinogen has been positively related to age and body-mass index (BMI) 2. Plasma 
fibrinogen has emerged as a strong predictor of arterial disease among both men and women 3 and this 
association was recently found in a population-based study among elderly subjects 4.  
Sex steroid hormones including both hormone therapy and endogenous sex steroid hormones may 
play an important role in the development of arterial disease. Despite compelling evidence for a 
cardioprotective effect of estrogens, randomized clinical trials have reported an increased risk of 
coronary heart disease among old women using hormone therapy as compared to non users 5. In 
addition, it is now well demonstrated that hormone therapy increases the risk of stroke among 
postmenopausal women 6, 7. By contrast, little is known on the association of endogenous sex steroid 
hormones with cardiovascular disease and results remain non significant 8-10.  
The relationship between sex steroid hormones and plasma fibrinogen has been studied in some 
different contexts and results are conflicting. It has been shown that postmenopausal hormone 
therapy slightly affects fibrinogen levels 11 while the association of fibrinogen with endogenous sex 
steroid hormones among peri/postmenopausal women led to inconclusive results 12-15. Nevertheless, 
an increase in plasma fibrinogen concentrations has been consistently observed during pregnancy, 
suggesting a positive and strong correlation between levels of circulating endogenous estrogens and 
plasma fibrinogen among young women 16-22. In this context, we hypothesized that plasma levels of 
endogenous estradiol could be positively related to plasma fibrinogen levels. Therefore, we 
investigated the association of fibrinogen with total estradiol (E2), total testosterone (T) and Sex 
Hormone Binding Globulin (SHBG) among postmenopausal women included in the Three-City (3C) 
study, a large community based prospective cohort study. 
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Methods 
 
Study population 
This study is part of the 3C study, a large ongoing French prospective cohort which aimed to evaluate 
the risk of dementia attributable to vascular disorders. The study protocol was approved by the Ethics 
Committee of the University Hospital of Kremlin-Bicêtre and each participant signed a written 
informed consent. A detailed methodology of the study has been previously described 23. Briefly, 
3,649 men and 5,645 women over 65 years registered on electoral rolls and not institutionalized were 
recruited in three French cities (Bordeaux, Dijon and Montpellier) between 1999 and 2001. Baseline 
data were collected by trained psychologists or nurses during a face to face interview using 
standardized questionnaires at home or at the study center. These data included information on socio-
demographic characteristics, education, medical history, medication use, food consumption and 
alcohol and tobacco use. Systolic and diastolic blood pressure, weight and height were assessed during 
a physical examination.  
Recently, a case-cohort study has been set-up from the 3C study to investigate the association of 
biological parameters with cardiovascular and dementia risk. In practice, the population study 
consists of a random subsample of the original cohort (the subcohort) and all the incident cases 
outside the subcohort. The methodology has been described in detail 24. The present analysis 
focused on women included in the subcohort (n=759). After exclusion of women who used 
hormone medication (n=120) or anticoagulation therapy (n=18) and subjects with a missing 
value regarding the fibrinogen measurement (n=19), this left 602 postmenopausal women.  
 
Baseline covariates 
Smoking status was studied in three categories (never, past, current). Body mass index 
(BMI) was calculated by dividing the weight by height in meters squared and 
overweight was defined as BMI superior or equal to 25 kg/m². Glycemia status was 
considered as “diabetes” if the fasting glycemia value at inclusion was superior or equal 
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to 1.26 g/L (7.00 mmol/L) and/or a treatment for diabetes, “high glycemia” if the value 
was between 1.10 and 1.26 g/L (6.10 and 7.00 mmol/L) and “normal glycemia” if 
glycemia was inferior to 1.10 g/L (6.10 mmol/L). Hypertension status was defined as 
high blood pressure measurement (systolic blood pressure superior or equal to 140 mm 
Hg and/or diastolic blood pressure superior or equal to 90 mm Hg) and/or an 
antihypertensive therapy at baseline. Hypercholesterolemia was considered present if 
the level of cholesterol was superior to 2.40 g/L at baseline and/or the subject was 
treated for hypercholesterolemia.  
 
Blood collection and biological measurements 
At baseline, fasting blood sample were collected for 90% of the entire cohort, including all the 
subjects selected for the case/cohort study. Citrated and EDTA plasmas were obtained after one 
centrifugation at 3.000g and immediately stored at -80°C in 500 microliters and 1 milliliter plastic 
tubes respectively.  
Fibrinogen was centrally measured in citrated plasmas using the kinetic method of Clauss (Dade 
Behring) with a minimum detectable concentration (MDC) of 0.2 g/l. The intraassay and interassay 
coefficient of variation (CV) were 0.97% and 2.6% respectively for a fibrinogen concentration of 2.69 
g/l. Data on fibrinogen measurement were missing for 19 women recruited in Bordeaux. These 
subjects did not differ from the other ones in term of age and traditional cardiovascular risk factors.  
Total E2, total T and SHBG were centrally measured in EDTA plasmas. Plasma total E2 was 
measured with a sensitive direct radioimmunoassay (RIA) on an Orion Diagnostica device (Spectria, 
Espoo, Finland) with a MDC of 2 pg/ml (7.3 pmol/l) that was arbitrarily assigned to the 38 subjects 
with no detectable estradiol concentration. The intraassay and interassay coefficients of variation (CV) 
were 17.6% and 18.1% for a total estradiol concentration of 3.2 pg/mL (12 pmol/L), respectively and 
2.8% and 5.8% for a total estradiol concentration of 24 pg/mL (88 pmol/L), respectively.  
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Plasma total T was measured by the same direct RIA as did total E2. The MDC was 0.02 ng/ml (0.06 
nmol/l) and the intraassay and interassay CV were 7.5% and 7.0% respectively for a total T 
concentration of 0.46 ng/ml and 0.35 ng/ml respectively (1.6 nmol/l and 1.2 nmol/l, respectively). 
Plasma SHBG was measured with a solid-phase chemiluminescent immunometric assay (Immulite®, 
Siemens Health Diagnostic Products, Caernarfon, Llanberis, UK) with a MDC of 0.02 nmol/l. The 
intraassay and interassay CV were respectively 3.2% and 4.6% for a SHBG concentration of 56 nmol/l 
25. 
 
Statistical analysis and covariates 
Baseline characteristics of subjects are presented as absolute numbers and percentages for categorical 
variables and arithmetic means and standard deviations (SD) for normal continuous variables. 
Variables which presented a positively skewed distribution were log-transformed and values were 
expressed as geometric means (GM) and interquartile range (IQR) as recommended 26.  
Linear regression analyses were used to test the association of fibrinogen with E2, T and SHBG. 
Regression coefficients were assessed in fibrinogen unit by 1 SD increase in the log-distribution of sex 
steroid hormones and SHBG. First adjustment included center, age, , hypercholesterolemia, glycemia 
status, hypertension  and smoking status. Models were further adjusted for other sex steroid hormones 
and SHBG (adjustment 2). Using a multiplicative linear model, an interaction of BMI with E2 on 
plasma fibrinogen was detected. Therefore, linear regression of fibrinogen on E2 was separately 
performed among women with BMI less than 25 kg/m² and among women with an overweight. 
Then, to assess the independence of the correlation between fibrinogen and E2, final adjustment 
within each stratum further included BMI as a continuous variable.  In addition, means of plasma 
fibrinogen were assessed by tertile of the E2 distribution in each stratum. Tests for linear trend across 
the three categories of sex steroid hormone were used to assess the significance of the variables in the 
models after having verified the linearity of the associations. To assess the linearity of the relation 
between E2and plasma fibrinogen levels, we used tests based on the difference in the log-likelihood 
between 2 models of prediction (one with 2 dummy variables corresponding to the tertile of the 
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parameter distribution and the other including the qualitative ordinal variable in 3 categories). All tests 
were not significant, and thus we did not reject the hypothesis of linearity. 
Statistical analyses were performed with the Statistical Analysis System software, version 9.2 (SAS 
Institute, Inc., Cary, NC). 
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Results 
 
Baseline characteristics of the subjects 
Baseline characteristics of the study population are presented in table 1. The final sample included 602 
women, aged 74.8 years (SD=5.5) on average. Regarding cardiovascular risk factors, 7.7% of women 
suffered from diabetes, 77.6% from hypertension, 63.5% from hypercholesterolemia and 48.2% were 
overweight. In addition, 84 (13.9%) subjects had a prevalent disorder. The mean fibrinogen level was 
3.42 g/l and GM of total E2, total T and SHBG were 5.29 pg/ml, 0.28 ng/ml and 26.3 nmol/l, 
respectively.  
 
Associations of plasma fibrinogen levels with sex steroid hormones and SHBG 
Association of fibrinogen with log-transformed total E2, total T and SHBG are given in the table 2. In 
univariate analysis, plasma fibrinogen levels were positively and significantly correlated to total E2 
( by 1 SD increase of total E2 in pg/ml =0.148, p<0.001). Adjustment for 
center and traditional cardiovascular risk factors including diabetes did not substantially change the 
result ( by 1 SD increase of total E2 in pg/ml=0.145, p<0.001). In addition, 
further adjustment for Total T and SHBG neither modify this association (of fibrinogen unit in g/l by 
1 SD increase of total E2 in pg/ml =0.147, p<0.001).  
With respect to T and SHBG, neither crude nor adjusted analysis showed a significant 
association with plasma fibrinogen. Furthermore, adding BMI in the full models did not change 
the results ( of fibrinogen unit in g/l by 1 SD increase of total T in ng/ml =0.015, p=0.59 and  of 
fibrinogen unit in g/l by 1 SD increase of total SHBG in nmol/l =-0.011, p=0.73). 
There was a significant interaction of total E2 with being overweight on plasma fibrinogen levels 
(figure 1). In a fully adjusted model including BMI, the association between total E2 and fibrinogen 
was of borderline significant for lean women while it was stronger for subjects who presented an 
overweight   of fibrinogen unit in g/l by 1 SD increase of total E2 in pg/ml=0.092, p=0.02 and   
of fibrinogen unit in g/l by 1 SD increase of total E2 in pg/ml=0.156, p<0.001, respectively, p for 
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interaction=0.04). Overweight women belonging to the third tertile of total E2 had an approximate 
15% increase in plasma fibrinogen concentrations compared to lean women with low total E2 levels.  
Stratified analyses showed no striking difference in the association of fibrinogen with sex steroid 
hormones and SHBG according to cardiovascular risk factors, including diabetes, 
hypercholesterolemia, hypertension and smoking.  
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Discussion 
 
To our knowledge, this is the first population-based study to show a positive and independent 
association of endogenous E2 with plasma fibrinogen among postmenopausal women who used 
neither hormone medication nor anticoagulation therapy. This association was significantly more 
pronounced among women who were overweight compared to lean ones. By contrast, neither T nor 
SHBG were associated with plasma fibrinogen levels.  
 
The association of plasma fibrinogen levels with endogenous E2 among peri/postmenopausal women 
was only investigated in two studies 12, 14. On one hand, Sowers et al. used the data of the Study of 
Women’s Health Across the Nation (SWAN) to describe the joint changes in haemostatic parameters 
and hormones concentrations among women transitioning to menopause 14. Results showed that 
changes in endogenous E2 during the menopausal transition were not associated with plasma 
fibrinogen variations. Although this study did not provide direct information on the association of 
endogenous estradiol with plasma fibrinogen among postmenopausal women, these data did not 
suggest that variation in endogenous sex steroid hormones could induce changes in plasma levels of 
fibrinogen. However, women included in the SWAN study were younger than the 3C Study 
participants and this difference in age between the two studies could in part explain this 
discrepancy. On the other hand, Folsom et al. investigated the association between endogenous sex 
steroid hormones and fibrinogen among postmenopausal women recruited in the Atherosclerosis 
Risk In Communities (ARIC) study 12. In this study, estrogen was positively associated with plasma 
fibrinogen and our results are concordant with these previous findings. 
With respect to total T and SHBG, our findings showing no relationship with plasma fibrinogen are 
concordant with the results from three studies which consistently found no association of fibrinogen 
with total T and SHBG 12, 13, 15.                             
 
Several biological mechanisms could explain the positive association of endogenous E2 with plasma 
fibrinogen. Fibrinogen is strongly implicated in coagulation processing but is also a systemic 
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inflammation marker. The mechanisms underlying the increase in plasma levels of fibrinogen jointly 
with an elevated concentration of circulating E2 might include both procoagulant and proinflammatory 
properties of endogenous E2. As observed in physiological models of hyperestrogeny such as 
pregnancy or ovarian stimulation, important increases in circulating E2 leads to a dramatically rise in 
procoagulant factors including fibrinogen and a decrease in fibrinolytic activity 16, 18-21, 27, 28. In 
addition, experimental studies in pregnant animals showed an up-regulation of liver fibrinogen 
biosynthesis by circulating E2 29. With respect to inflammatory processing, endogenous E2 has been 
shown to be positively and significantly associated with plasma levels of C-reactive protein among 
postmenopausal women 30, 31. These findings suggest that high levels of endogenous E2 could induce 
both a procoagulant and a proinflammatory state in postmenopausal women. 
Adipose tissue might play a role in modifying the association of fibrinogen with circulating E2. 
Obesity is characterized by a deleterious haemostatic profile and a low grade inflammation state which 
can result from both a direct and an indirect processing. On one hand, adipocyte hypertrophy and 
hyperplasia directly result in a secretion of adipokines which are implicated in both production of 
proinflammatory proteins and induce a hypofribrinolys and prothrombotic state 32, 33. On the other 
hand, an inflammation state in obese subjects can indirectly result from the increase in testosterone 
aromatization to product E2 which has inflammatory and procoagulant properties 34. The direct 
mechanism seems to be predominant in the deleterious haemostatic profile and the low grade 
inflammation state of obese subjects as showed by our data where the positive correlation between 
BMI and fibrinogen (r=0.18, p<0.001) remained significant after adjustment for total E2 (r=0.14, 
p<0.001). Since haemostasis and inflammation are closely linked in the context of atherosclerosis, it is 
conceivable to hypothesize that E2 could interact with inflammatory and procoagulant factors directly 
secreted by adipose tissue to increase the plasma fibrinogen, the levels of which are enhanced in 
atherosclerosis 35. 
 
Our study presented strengths and limitations including the study design, the biological measurements 
and the potential confounders in the statistical analysis.  
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First, this analysis was carried out on an important number of subjects randomly selected from a 
population-based cohort study. In addition, baseline data were collected by standardized 
questionnaires during a face-to-face interview. However, the cross-sectional study design might not be 
adequate to determine whether changes in plasma fibrinogen levels were a consequence of E2 
variations or the reverse.  
With respect to the sex steroid hormones assays, especially at low levels of estradiol in 
postmenopausal women, conventional RIAs with preceding purification steps would provide more 
reliable and accurate measurements of plasma estradiol as compared with direct RIA 36. However, 
measurement error related to direct RIA would bias our analysis towards the null hypothesis, resulting 
in a potential underestimation of the true associations. 
Finally, we could not exclude the fact that other confounders could explain our findings of an 
association between total E2 and plasma fibrinogen. However, adjustment for several cardiovascular 
risk factors did not change the results.  
  
In conclusion, our results show a positive and independent association of total E2 with plasma 
fibrinogen levels among postmenopausal women, especially in subjects who were overweight. Plasma 
fibrinogen is a strong predictor of cardiovascular disease. Therefore, identifying new factors which 
independently modify plasma fibrinogen levels may be important to improve the cardiovascular risk 
stratification and disease prevention. Since the 3C case/cohort study has shown that high level of 
estradiol represented a new predictor of cardiovascular disease among older postmenopausal 
women 37, it would be now of interest to investigate whether difference in plasma fibrinogen 
concentrations could explain part of the association of endogenous estradiol with the risk of 
ischemic arterial disease among older postmenopausal women.  
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Figure 1. Adjusted means of fibrinogen according to the tertiles of total estradiol by overweight status 
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Table 1. Baseline characteristics of the women selected within the subcohort sample in the 3C Study (n=602) 
Characteristics 
  
Value 
    
      
Age (years)   74.8 (5.5)     
            
Body-mass index (kg/m²)   25.6 (4.6)     
  Body-mass index≥25 kg/m²   287 (48.2)     
            
Education           
  Less than grade school   229 (38.0)     
  Grade school or high school   187 (31.1)     
  High school validated or university   186 (30.9)     
            
Natural menopause   474 (91.2)     
            
Smoking status         
  Never   489 (81.2)     
  Past     87 (14.5)     
  Current     26 (  4.3)     
            
Hypertension   467 (77.6)     
            
Glycemia     
 
    
  Normal glycemia   534 (88.8)     
  High glycemia     21 (  3.5)     
  Diabetes     46 (  7.7)     
            
Hypercholesterolemia   382 (63.5)     
            
Prevalent disorder*         
  Coronary heart disease     53 (  8.8)     
  Stroke     25 (  4.2)     
  Dementia     13 (  2.2)     
            
Biological parameters         
  Total E2 (pg/ml)   5.29 (3.54-8.32)     
  Total T (ng/ml)   0.28 (0.20-0.45)     
  SHBG (nmol/l)   26.3 (18.2-38.1)     
  Fibrinogen (g/l)   3.42 (0.65)     
            
Data are given as n(%) or arithmetic means (SD) except for steroid sex hormones expressed as 
geometric means (interquartile range) 
* 7 subjects presentend more than one prevalent disorder     
E2: estradiol         
T: testosterone         
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Table 2. Association of fibrinogen with total E2, total T and SHBG assessed in linear regression  
models in the 3C study 
                              
    Fibrinogen, g/l     
    Crude   Adjustment 1   Adjustment 2     
     SE p value    SE p value    SE p value     
    

      

      

        
Total E2, pg/ml (log)   0.148 0.027 <0.001   0.145 0.026 <0.001   0.147 0.029 <0.001     
Total T, ng/ml (log)   0.019 0.027 0.49   0.025 0.027 0.36   
 
0.003 0.027 0.92     
SHBG, nmol/l (log)   -0.041 0.027 0.13   
 
-0.050 0.028 0.10   0.008 0.030 0.78     
                              
 
  E2: estradiol 
T: Testosterone 
Adjustment 1: adjustment for center, age, hypertension, diabetes, hypercholesterolemia and 
smoking status 
Adjustement 2: adjustment for center, age, hypertension, diabetes, hypercholesterolemia, smoking 
status and other steroid sex hormones   
* beta-coefficient of fibrinogen unit for 1 SD increment in the log-distribution of steroid sex 
hormones and SHBG 
 
Fibrinogen and Sex steroid hormones  Revised final version 
 
20/20 
 
 
2.9 
3 
3.1 
3.2 
3.3 
3.4 
3.5 
3.6 
3.7 
1 2 
p for trend<0.001 p for trend=0.03 
Tertile 1 
Figure 1. Adjusted means* of fibrinogen according to the tertiles of total estradiol by  
overweight status 
p for interaction=0.04  # 
* Adjusted for center, age, BMI, hypertension, diabetes, hypercholesterolemia and smoking status 
# Total estradiol and BMI were used as continuous variables 
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